Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Depreciation & Amortization (CF): 2013-2025

Historic Depreciation & Amortization (CF) for Ocular Therapeutix (OCUL) over the last 12 years, with Sep 2025 value amounting to $1.1 million.

  • Ocular Therapeutix's Depreciation & Amortization (CF) rose 11.47% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year increase of 6.17%. This contributed to the annual value of $3.8 million for FY2024, which is 26.92% up from last year.
  • Latest data reveals that Ocular Therapeutix reported Depreciation & Amortization (CF) of $1.1 million as of Q3 2025, which was up 4.19% from $1.0 million recorded in Q2 2025.
  • In the past 5 years, Ocular Therapeutix's Depreciation & Amortization (CF) ranged from a high of $1.1 million in Q3 2025 and a low of $483,000 during Q1 2023.
  • In the last 3 years, Ocular Therapeutix's Depreciation & Amortization (CF) had a median value of $956,000 in 2024 and averaged $895,000.
  • Per our database at Business Quant, Ocular Therapeutix's Depreciation & Amortization (CF) decreased by 14.54% in 2021 and then surged by 95.11% in 2023.
  • Over the past 5 years, Ocular Therapeutix's Depreciation & Amortization (CF) (Quarterly) stood at $570,000 in 2021, then dropped by 13.86% to $491,000 in 2022, then soared by 95.11% to $958,000 in 2023, then dropped by 0.73% to $951,000 in 2024, then climbed by 11.47% to $1.1 million in 2025.
  • Its last three reported values are $1.1 million in Q3 2025, $1.0 million for Q2 2025, and $981,000 during Q1 2025.